Azacytidine impairs NK cell reactivity while decitabine augments NK cell responsiveness toward stimulation

International Journal of Cancer

Volumn 128, Issue 12, 2011, Pages 2911-2922

  Schmiedel, Benjamin J ^a   Arélin, Viktor ^a   Gruenebach, Frank ^a   Krusch, Matthias ^a   Schmidt, Susanne M ^a   Salih, Helmut R ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

azacytidine; decitabine; NK cells

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; GAMMA INTERFERON; HLA A ANTIGEN; HLA B ANTIGEN; MESSENGER RNA; NATURAL KILLER CELL RECEPTOR NKG2D;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER IMMUNOLOGY; CELL DIVISION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DNA DETERMINATION; DRUG TARGETING; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; LYMPHOCYTE ACTIVATION; LYMPHOCYTE CULTURE; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; PRIORITY JOURNAL; RNA SYNTHESIS;

AZACITIDINE; CELL LINE; CELL PROLIFERATION; CYTOTOXICITY, IMMUNOLOGIC; HUMANS; IMMUNITY, INNATE; INTERFERON-GAMMA; KILLER CELLS, NATURAL;

EID: 79955413027     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25635     Document Type: Article

References (35)

1. Stresemann C, Lyko F,. Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine. Int J Cancer 2008; 123: 8-13. (Pubitemid 351705186)
2. Issa JP,. DNA methylation as a therapeutic target in cancer. Clin Cancer Res 2007; 13: 1634-7.
3. Atallah E, Garcia-Manero G,. Use of hypomethylating agents in myelodysplastic syndromes. Clin Adv Hematol Oncol 2007; 5: 544-52. (Pubitemid 47499911)
4. Stone R, Sekeres M, Garcia-Manero G,. Evolving strategies in the treatment of MDS and AML. Clin Adv Hematol Oncol 2009; 7: 1-14.
5. Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G,. Immunological aspects of cancer chemotherapy. Nat Rev Immunol 2008; 8: 59-73.
6. Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S,. Functions of natural killer cells. Nat Immunol 2008; 9: 503-10. (Pubitemid 351560519)
7. Ruggeri L, Mancusi A, Burchielli E, Aversa F, Martelli MF, Velardi A,. Natural killer cell alloreactivity in allogeneic hematopoietic transplantation. Curr Opin Oncol 2007; 19: 142-7. (Pubitemid 46204354)
8. Demanet C, Mulder A, Deneys V, Worsham MJ, Maes P, Claas FH, Ferrone S,. Down-regulation of HLA-A and HLA-Bw6, but not HLA-Bw4, allospecificities in leukemic cells: an escape mechanism from CTL and NK attack? Blood 2004; 103: 3122-30. (Pubitemid 38451690)
9. Lowdell MW, Craston R, Samuel D, Wood ME, O'Neill E, Saha V, Prentice HG,. Evidence that continued remission in patients treated for acute leukaemia is dependent upon autologous natural killer cells. Br J Haematol 2002; 117: 821-7. (Pubitemid 34639242)
10. Pierson BA, Miller JS,. CD56+bright and CD56+dim natural killer cells in patients with chronic myelogenous leukemia progressively decrease in number, respond less to stimuli that recruit clonogenic natural killer cells, and exhibit decreased proliferation on a per cell basis. Blood 1996; 88: 2279-87. (Pubitemid 26307932)
11. Tajima F, Kawatani T, Endo A, Kawasaki H,. Natural killer cell activity and cytokine production as prognostic factors in adult acute leukemia. Leukemia 1996; 10: 478-82. (Pubitemid 26128788)
12. Epling-Burnette PK, Bai F, Painter JS, Rollison DE, Salih HR, Krusch M, Zou J, Ku E, Zhong B, Boulware D, Moscinski L, Wei S, et al. Reduced natural killer (NK) function associated with high-risk myelodysplastic syndrome (MDS) and reduced expression of activating NK receptors. Blood 2007; 109: 4816-24. (Pubitemid 46827777)
13. Kiladjian JJ, Bourgeois E, Lobe I, Braun T, Visentin G, Bourhis JH, Fenaux P, Chouaib S, Caignard A,. Cytolytic function and survival of natural killer cells are severely altered in myelodysplastic syndromes. Leukemia 2006; 20: 463-70. (Pubitemid 43291745)
14. Santourlidis S, Trompeter HI, Weinhold S, Eisermann B, Meyer KL, Wernet P, Uhrberg M,. Crucial role of DNA methylation in determination of clonally distributed killer cell Ig-like receptor expression patterns in NK cells. J Immunol 2002; 169: 4253-61. (Pubitemid 35178197)
15. Chan HW, Kurago ZB, Stewart CA, Wilson MJ, Martin MP, Mace BE, Carrington M, Trowsdale J, Lutz CT,. DNA methylation maintains allele-specific KIR gene expression in human natural killer cells. J Exp Med 2003; 197: 245-55. (Pubitemid 36152318)
16. Gao XN, Lin J, Wang LL, Yu L,. Demethylating treatment suppresses natural killer cell cytolytic activity. Mol Immunol 2009; 46: 2064-70.
17. Baltz KM, Krusch M, Bringmann A, Brossart P, Mayer F, Kloss M, Baessler T, Kumbier I, Peterfi A, Kupka S, Kroeber S, Menzel D, et al. Cancer immunoediting by GITR (glucocorticoid-induced TNF-related protein) ligand in humans: NK cell/tumor cell interactions. FASEB J 2007; 21: 2442-54. (Pubitemid 47230674)
18. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C,. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 1991; 139: 271-9.
19. Marcucci G, Silverman L, Eller M, Lintz L, Beach CL,. Bioavailability of azacitidine subcutaneous versus intravenous in patients with the myelodysplastic syndromes. J Clin Pharmacol 2005; 45: 597-602. (Pubitemid 40562951)
20. Momparler RL, Bouffard DY, Momparler LF, Dionne J, Belanger K, Ayoub J,. Pilot phase I-II study on 5-aza-2â-deoxycytidine (Decitabine) in patients with metastatic lung cancer. Anticancer Drugs 1997; 8: 358-68. (Pubitemid 27204954)
21. Ishii KJ, Akira S,. Potential link between the immune system and metabolism of nucleic acids. Curr Opin Immunol 2008; 20: 524-9.
22. Tang KF, He CX, Zeng GL, Wu J, Song GB, Shi YS, Zhang WG, Huang AL, Steinle A, Ren H,. Induction of MHC class I-related chain B (MICB) by 5-aza-2â-deoxycytidine. Biochem Biophys Res Commun 2008; 370: 578-83.
23. Rohner A, Langenkamp U, Siegler U, Kalberer CP, Wodnar-Filipowicz A,. Differentiation-promoting drugs up-regulate NKG2D ligand expression and enhance the susceptibility of acute myeloid leukemia cells to natural killer cell-mediated lysis. Leuk Res 2007; 31: 1393-402. (Pubitemid 47212430)
24. Ljunggren HG, Malmberg KJ,. Prospects for the use of NK cells in immunotherapy of human cancer. Nat Rev Immunol 2007; 7: 329-39.
25. Terme M, Ullrich E, Delahaye NF, Chaput N, Zitvogel L,. Natural killer cell-directed therapies: moving from unexpected results to successful strategies. Nat Immunol 2008; 9: 486-94. (Pubitemid 351560517)
26. Sandmaier BM, Mackinnon S, Childs RW,. Reduced intensity conditioning for allogeneic hematopoietic cell transplantation: current perspectives. Biol Blood Marrow Transplant 2007; 13: 87-97. (Pubitemid 46044111)
27. Markasz L, Stuber G, Vanherberghen B, Flaberg E, Olah E, Carbone E, Eksborg S, Klein E, Skribek H, Szekely L,. Effect of frequently used chemotherapeutic drugs on the cytotoxic activity of human natural killer cells. Mol Cancer Ther 2007; 6: 644-54. (Pubitemid 46332465)
28. Armeanu S, Bitzer M, Lauer UM, Venturelli S, Pathil A, Krusch M, Kaiser S, Jobst J, Smirnow I, Wagner A, Steinle A, Salih HR,. Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate. Cancer Res 2005; 65: 6321-9. (Pubitemid 40994418)
29. Skov S, Pedersen MT, Andresen L, Straten PT, Woetmann A, Odum N,. Cancer cells become susceptible to natural killer cell killing after exposure to histone deacetylase inhibitors due to glycogen synthase kinase-3-dependent expression of MHC class I-related chain A and B. Cancer Res 2005; 65: 11136-45. (Pubitemid 41713385)
30. Hoskin DW, Mader JS, Furlong SJ, Conrad DM, Blay J,. Inhibition of T cell and natural killer cell function by adenosine and its contribution to immune evasion by tumor cells (Review). Int J Oncol 2008; 32: 527-35. (Pubitemid 351330458)
31. Girart MV, Fuertes MB, Domaica CI, Rossi LE, Zwirner NW,. Engagement of TLR3, TLR7, and NKG2D regulate IFN-gamma secretion but not NKG2D-mediated cytotoxicity by human NK cells stimulated with suboptimal doses of IL-12. J Immunol 2007; 179: 3472-9.
32. Vesely J,. Mode of action and effects of 5-azacytidine and of its derivatives in eukaryotic cells. Pharmacol Ther 1985; 28: 227-35. (Pubitemid 16219484)
33. Rai K, Huggins IJ, James SR, Karpf AR, Jones DA, Cairns BR,. DNA demethylation in zebrafish involves the coupling of a deaminase, a glycosylase, and gadd45. Cell 2008; 135: 1201-12.
34. Barreto G, Schafer A, Marhold J, Stach D, Swaminathan SK, Handa V, Doderlein G, Maltry N, Wu W, Lyko F, Niehrs C,. Gadd45a promotes epigenetic gene activation by repair-mediated DNA demethylation. Nature 2007; 445: 671-5. (Pubitemid 46232889)
35. Bruniquel D, Schwartz RH,. Selective, stable demethylation of the interleukin-2 gene enhances transcription by an active process. Nat Immunol 2003; 4: 235-40. (Pubitemid 36322132)